Measuring pharmacogenetics in special groups: Geriatrics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 7, 2015, Pages 1073-1088

  Seripa, Davide ^a   Panza, Francesco ^a,b   Daragjati, Julia ^a   Paroni, Giulia ^a   Pilotto, Alberto ^c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

CYP; DNA methylation; Epigenetics; Geriatrics; Pharmacogenetics

Indexed keywords

CYTOCHROME P450;

AGE; AGED; CLINICAL PRACTICE; DNA METHYLATION; DRUG METABOLISM; DRUG RESPONSE; DRUG USE; EPIGENETICS; EVOLUTION; GENE CONTROL; GENE EXPRESSION; GERIATRICS; HUMAN; PHARMACOGENETICS; PHENOTYPE; REVIEW; ADVERSE DRUG REACTION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM;

AGE FACTORS; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DNA METHYLATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 84931051597     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1041919     Document Type: Review

References (112)

1. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008;31:545-56
2. Petrovic M, van der Cammen T, Onder G. Adverse drug reactions in older people: detection and prevention. Drugs Aging 2012;29:453-62
3. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9
4. Miguel A, Azevedo LF, Araujo M, et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012;21:1139-54
5. AHRQ-Agency for Healthcare Research and Quality, Advancing Excellence in Health Care. Reducing and preventing adverse drug events to decrease hospital costs. Research in action Available from: http://archive.ahrq.gov/research/findings/factsheets/errors-safety/aderia/ade.html
6. Marcum ZA, Pugh MJ, Amuan ME, et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J Gerontol A Biol Sci Med Sci 2012;67:867-74
7. Patel RS, Marcum ZA, Peron EP, et al. Prevalence of and factors associated with therapeutic failure-related hospitalizations in the elderly. Consult Pharm 2014;29:376-86
8. Motulsky AG. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 1957;165:835-7
9. Vogel F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 1959;12:52-125
10. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71
11. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001;22:298-305
12. Güzey C, Spigset O. Genotyping as a tool to predict adverse drug reactions. Curr Top Med Chem 2004;4:1411-21
13. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-16
14. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637-9
15. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76:391-6
16. Seripa D, Pilotto A, Panza F, et al. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 2010;9:457-74
17. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 2011;120:1-13
18. Schuler MA. The role of cytochrome P450 monooxygenases in plant-insect interactions. Plant Physiol 1996;112:1411-19
19. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990;6:182-6
20. Nelson DR. Metazoan cytochrome P450 evolution. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;121:15-22
21. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-9
22. Pilotto A, Panza F, Seripa D. Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice. Curr Drug Metab 2011;12(7):621-34
23. Seripa D, Paroni G, Urbano M, et al. Pharmacogenetics in older people: what we know and what we need to know. J Nephrol 2012;25(Suppl 19):S38-47
24. Thomas JH. Rapid birth-death evolution specific to xenobiotic cytochrome P450 genes in vertebrates. PLoS Genet 2007;3:e67
25. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83-448
26. Molecular basis of disease. Cytochrome P450s in humans. Available from: http://drnelson.uthsc.edu/P450.talks.html
27. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol 2006;320:183-91
28. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Allele nomenclature for Cytochrome P450 enzymes. Available from: http://www.cypalleles.ki.se/
29. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993;57:129-60
30. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-9
31. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91
32. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90
33. Preissner SC, Hoffmann MF, Preissner R, et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE 2013;8:e82562
34. Caraco Y. Genes and the response to drugs. N Engl J Med 2004;351:2867-9
35. de Leon J, Arranz MJ, Ruanõ G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008;28:599-617
36. Crick F. Central dogma of molecular biology. Nature 1970;227:561-3
37. Petronis A, Gottesman II, Kan P, et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull 2003;29:169-78
38. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-9
39. Baer-Dubowska W, Majchrzak-Celinska M, Cichocki M. Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 2011;63:293-304
40. Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 2011;89:902-7
41. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009;23:781-3
42. Mukherjee K, Twyman RM, Vilcinskas A. Insects as models to study the epigenetic basis of disease. Prog Biophys Mol Biol 2015;doi: 10.1016/j. pbiomolbio.2015.02.009
43. Steves CJ, Spector TD, Jackson SH. Ageing, genes, environment and epigenetics: what twin studies tell us now, and in the future. Age Ageing 2012;41:581-6
44. Casadesus J, Low D. Epigenetic gene regulation in the bacterial world. Microbiol Mol Biol Rev 2006;70:830-56
45. Zemach A, McDaniel IE, Silva P, et al. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 2010;328:916-19
46. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006;31:89-97
47. Reddington JP, Pennings S, Meehan RR. Non-canonical functions of the DNA methylome in gene regulation. Biochem J 2013;451:13-23
48. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998;19:219-20
49. Xie S, Wang Z, Okano M, et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 1999;236:87-95
50. Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004;61:2571-87
51. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissuespecific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5:e1000602
52. Shoemaker R, Deng J, Wang W, et al. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res 2010;20:883-9
53. Kerkel K, Spadola A, Yuan E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequencedependent allele-specific DNA methylation. Nat Genet 2008;40:904-8
54. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526
55. Hirota T, Takane H, Higuchi S, et al. Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Curr Drug Metab 2008;9:34-8
56. Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009;85:426-30
57. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 2009;10:1067-76
58. Tang J, Xiong Y, Zhou HH, et al. DNA methylation and personalized medicine. J Clin Pharm Ther 2014;39:621-7
59. Zanger UM, Klein K, Thomas M, et al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. Clin Pharmacol Ther 2014;95:258-61
60. Naselli F, Catanzaro I, Bellavia D, et al. Role and importance of polymorphisms with respect to DNA methylation for the expression of CYP2E1 enzyme. Gene 2014;536:29-39
61. Rodriguez-Antona C, Gomez A, Karlgren M, et al. Molecular genetics and epigenetics of cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010;127:1-17
62. Nakajima M, Iwanari M, Yokoi T. Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett 2003;144:247-56
63. Okino ST, Pookot D, Li LC, et al. Epigenetic inactivation of the dioxinresponsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res 2006;66:7420-8
64. Anttila S, Hakkola J, Tuominen P, et al. Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res 2003;63:8623-8
65. Hammons GJ, Yan-Sanders Y, Jin B, et al. Specific site methylation in the 5′-flanking region of CYP1A2 interindividual differences in human livers. Life Sci 2001;69:839-45
66. Ghotbi R, Gomez A, Milani L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009;9:208-17
67. Tokizane T, Shiina H, Igawa M, et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 2005;11:5793-801
68. Habano W, Gamo T, Sugai T, et al. CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol 2009;34:1085-91
69. Kerkel K, Spadola A, Yuan E, et al. Genomic surveys by methylation-sensitive SNP analysis-identify sequencedependent-allele-specific DNA methylation. Nat Genet 2008;40:904-8
70. Jones SM, Boobis AR, Moore GE, et al. Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem Pharmacol 1992;43:1876-9
71. Oneta CM, Lieber CS, Li J, et al. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol, and disappearance during withdrawal phase. J Hepatol 2002;36:47-52
72. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006;7:181
73. Kacevska M, Ivanov M, Wyss A, et al. A methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 2012;94:2338-44
74. Novakovic B, Sibson M, Ng HK, et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 2009;284:14838-48
75. Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol 2010;121:338-42
76. Penaloza CG, Estevez B, Han DM, et al. Sex-dependent regulation of cytochrome P450 family members CYP1A1, CYP2E1, and CYP7B1 by methylation of DNA. FASEB J 2014;28:966-77
77. Cosentino C, Mostoslavsky R. Metabolism, longevity and epigenetics. Cell Mol Life Sci 2013;70:1525-41
78. Boyd-Kirkup JD, Green CD, Wu G, et al. Epigenomics and the regulation of aging. Epigenomics 2013;5:205-27
79. Brunet A, Berger SL. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci 2014;69:17-20
80. Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest 2014;124:24-9
81. Johnson AA, Akman K, Calimport SR, et al. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res 2012;15:483-94
82. Ben-Avraham D, Muzumdar RH, Atzmon G. Epigenetic genome-wide association methylation in aging and longevity. Epigenomics 2012;4:503-9
83. Li Y, Liu Y, Strickland FM, et al. Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp Gerontol 2010;45:312-22
84. Oliveira AM, Hemstedt TJ, Bading H. Rescue of aging-associated decline in DNMT3a2 expression restores cognitive abilities. Nat Neurosci 2012;15:1111-13
85. Guo JU, Ma DK, Mo H, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 2011;14:1345-51
86. Talens RP, Christensen K, Putter H, et al. Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell 2012;11:694-703
87. Hernandez DG, Nalls MA, Gibbs JR, et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet 2011;20:1164-72
88. Martin GM. Epigenetic drift in aging identical twins. Proc Natl Acad Sci USA 2005;102:10413-14
89. Gronniger E, Weber B, Heil O, et al. Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS Genet 2010;6:e1000971
90. Rakyan VK, Down TA, Maslau S, et al. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res 2010;20:434-9
91. Bjornsson HT, Sigurdsson MI, Fallin MD, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 2008;299:2877-83
92. Bollati V, Schwartz J, Wright R, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev 2009;130:234-9
93. Liu L, van Groen T, Kadish I, et al. Insufficient DNA methylation affects healthy aging and promotes age-related health problems. Clin Epigenet 2011;2:349-60
94. Heyn H, Li N, Ferreira HJ, et al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci USA 2012;109:10522-7
95. Casillas MA Jr, Lopatina N, Andrews LG, et al. Transcriptional control of the DNA methyltransferases is altered in aging and neoplasticallytransformed human fibroblasts. Mol Cell Biochem 2003;252:33-43
96. Kwak HC, Kim HC, Oh SJ, Kim SK. Effects of age increase on hepatic expression and activity of cytochrome P450 in male C57BL/6 mice. Arch Pharm Res 2014;DOI; 10.1007/s12272-014-0452-z
97. Feser J, Tyler J. Chromatin structure as a mediator of aging. FEBS Lett 2011;585:2041-8
98. O'Sullivan RJ, Karlseder J. The great unravelling: chromatin as a modulator of the aging process. Trends Biochem Sci 2012;37:466-47
99. Liu L, Cheung TH, Charville GW, et al. Chromatin modifications as determinants of muscle stem cell quiescence and chronological aging. Cell Rep 2013;4:189-204
100. Maures TJ, Greer EL, Hauswirth AG, et al. The H3K27 demethylase UTX-1 regulates C.elegans lifespan in a germline-independent, insulin-dependent manner. Aging Cell 2011;10:980-90
101. Wood JG, Hillenmeyer S, Lawrence C, et al. Chromatin remodeling in the aging genome of Drosophila. Aging Cell 2010;9:971-8
102. Price BD, D'Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 2013;152:1344-54
103. McCauley BS, Dang W. Histone methylation and aging: lessons learned frommodel systems. BiochimBiophys Acta 2014;1839:1454-62
104. Harries LW. MicroRNAs as mediators of the ageing process. Genes (Basel) 2014;5:656-70
105. Jung HJ, Suh Y. Circulating miRNAs in ageing and ageing-related diseases. J Genet Genomics 2014;41:465-72
106. Kacevska M, Ivanov M, Ingelman-Sundberg M. Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics 2012;13:1373-85
107. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science 2010;328:321-6
108. Omodei D, Fontana L. Calorie restriction and prevention of ageassociated chronic disease. FEBS Lett 2011;585:1537-42
109. Fontana L, Kennedy BK, Longo VD, et al. Medical research: treat ageing. Nature 2014;511:405-7
110. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem 2011;22:1879-903
111. Jeelani S, Reddy RC, Maheswaran T, et al. Theranostics: A treasured tailor for tomorrow. J Pharm Bioallied Sci 2014;6(Suppl 1):S6-8
112. Bartlett G, Antoun J, Zgheib NK. Theranostics in primary care: pharmacogenomics tests and beyond. Expert Rev Mol Diagn 2012;12:841-55